SGLT Inhibition: It’s Not Just for Type 2 Anymore
Can a drug long-used for type 2 diabetes, also help those with T1D? The European body that approves medicines for human-use thinks so.
We’re the Advancing Progress Type
Breakthrough T1D Fiscal Year 2018 Annual Report As you’ll see in the pages of our fiscal year 2018 annual report, together, we are making incredible strides in our fight to cure, prevent and treat type 1 diabetes (T1D) and its complications. In fact, 2018 was one of the most exciting years yet for T1D research. […]
GK Activator Clinical Trial Results
A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body, and its expression is limited to tissues that require sugar-sensing, mainly the liver and pancreatic beta cells. If blood glucose levels are deemed too high, activation of GK in the liver increases glucose utilization which in turn lowers blood glucose.
Breakthrough T1D Leads Push to Develop a Vaccine for Viral Infections that Could Trigger T1D
Scientists worldwide are attempting to determine why some people predisposed to type 1 diabetes (T1D) eventually end up developing the disease. There is a genetic component involved, but that alone will not provide an answer for the 64,000 people who develop T1D in the United States each year, who, for the most part, lack any […]
An Important Step in the FDA Review of Sotagliflozin (Zynquista™) for T1D
You’ll hear it again and again: For some people with type 1 diabetes (T1D), SGLT inhibitor therapy* means taking less insulin, having increased time in range, reducing the minute-to-minute glucose variability, contributing to weight loss and lowering your A1c. But you’ll also hear about the risks. From dehydration and constant urination to urinary tract infections […]
